{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:49:42Z","timestamp":1793126982951,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01658-7","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T09:08:27Z","timestamp":1737450507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Short-term variability of Alzheimer\u2019s disease plasma biomarkers in a mixed memory clinic cohort"],"prefix":"10.1186","volume":"17","author":[{"given":"Frederikke Kragh","family":"Clemmensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias Holsey","family":"Gramkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Hviid","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Waldemar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen Gregers","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Steen","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"Suppl 2","key":"1658_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40120-019-00164-5","volume":"8","author":"D Li","year":"2019","unstructured":"Li D, Mielke MM. An update on blood-based markers of Alzheimer\u2019s disease using the SiMoA platform. Neurol Ther. 2019;8(Suppl 2):73\u201382.","journal-title":"Neurol Ther"},{"issue":"5","key":"1658_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3(5):506\u201319.","journal-title":"Nat Aging"},{"issue":"9","key":"1658_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging. 2023;3(9):1079\u201390.","journal-title":"Nat Aging."},{"issue":"17","key":"1658_CR4","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359.","journal-title":"Neurology."},{"issue":"11","key":"1658_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allu\u00e9 JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375\u201382.","journal-title":"JAMA Neurol."},{"issue":"7","key":"1658_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18(7):400\u201318.","journal-title":"Nat Rev Neurol."},{"key":"1658_CR7","doi-asserted-by":"publisher","first-page":"117229","DOI":"10.1016\/j.jns.2020.117229","volume":"420","author":"S Ramani","year":"2021","unstructured":"Ramani S, Berard JA, Walker LAS. The relationship between neurofilament light chain and cognition in neurological disorders: a scoping review. J Neurol Sci. 2021;420:117229.","journal-title":"J Neurol Sci."},{"issue":"1","key":"1658_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-01137-1","volume":"11","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease. Transl Psychiatry. 2021;11(1):1\u201310.","journal-title":"Transl Psychiatry."},{"issue":"12","key":"1658_CR9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(12):1250\u20139.","journal-title":"JAMA Neurol."},{"key":"1658_CR10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.dadm.2018.06.001","volume":"10","author":"A Keshavan","year":"2018","unstructured":"Keshavan A, Heslegrave A, Zetterberg H, Schott JM. Stability of blood-based biomarkers of Alzheimer\u2019s disease over multiple freeze-thaw cycles. Alzheimers Dement Amst Neth. 2018;10:448\u201351.","journal-title":"Alzheimers Dement Amst Neth"},{"issue":"8","key":"1658_CR11","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease\u2013related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484\u201397.","journal-title":"Alzheimers Dement."},{"issue":"2","key":"1658_CR12","first-page":"e12439","volume":"15","author":"AL Sunde","year":"2023","unstructured":"Sunde AL, Alsnes IV, Aarsland D, Ashton NJ, Tovar-Rios DA, De Santis G, et al. Preanalytical stability of plasma biomarkers for Alzheimer\u2019s disease pathology. Alzheimers Dement Diagn Assess Dis Monit. 2023;15(2):e12439.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit."},{"issue":"2","key":"1658_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3233\/JAD-230384","volume":"95","author":"D Panikkar","year":"2023","unstructured":"Panikkar D, Vivek S, Crimmins E, Faul J, Langa KM, Thyagarajan B. Pre-analytical variables influencing stability of blood-based biomarkers of neuropathology. J Alzheimers Dis JAD. 2023;95(2):735\u201348.","journal-title":"J Alzheimers Dis JAD"},{"issue":"S15","key":"1658_CR14","doi-asserted-by":"publisher","first-page":"e077508","DOI":"10.1002\/alz.077508","volume":"19","author":"EL Vasquez","year":"2023","unstructured":"Vasquez EL, Kautz TF, Kivis\u00e4kk P, Satizabal CL, Bernal R, Seshadri S, et al. The effect of fasting status on Alzheimer\u2019s disease plasma biomarkers AB40, AB42, GFAP, NfL, CD-14, and YKL-40. Alzheimers Dement. 2023;19(S15):e077508.","journal-title":"Alzheimers Dement."},{"issue":"12","key":"1658_CR15","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1002\/alz.13163","volume":"19","author":"H Huber","year":"2023","unstructured":"Huber H, Ashton NJ, Schieren A, Montoliu-Gaya L, Molfetta GD, Brum WS, et al. Levels of Alzheimer\u2019s disease blood biomarkers are altered after food intake\u2014a pilot intervention study in healthy adults. Alzheimers Dement. 2023;19(12):5531\u201340.","journal-title":"Alzheimers Dement."},{"issue":"3","key":"1658_CR16","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1212\/WNL.0000000000207419","volume":"101","author":"A Dittrich","year":"2023","unstructured":"Dittrich A, Ashton NJ, Zetterberg H, Blennow K, Zettergren A, Simr\u00e9n J, et al. Association of chronic kidney disease with plasma NfL and other biomarkers of neurodegeneration: the H70 birth cohort study in Gothenburg. Neurology. 2023;101(3):e277\u201388.","journal-title":"Neurology."},{"issue":"14","key":"1658_CR17","doi-asserted-by":"publisher","first-page":"e1402","DOI":"10.1212\/WNL.0000000000207675","volume":"101","author":"VK Ramanan","year":"2023","unstructured":"Ramanan VK, Graff-Radford J, Syrjanen J, Shir D, Algeciras-Schimnich A, Lucas J, et al. Association of plasma biomarkers of Alzheimer disease with cognition and medical comorbidities in a biracial cohort. Neurology. 2023;101(14):e1402\u201311.","journal-title":"Neurology."},{"issue":"1","key":"1658_CR18","doi-asserted-by":"publisher","first-page":"e2252387","DOI":"10.1001\/jamanetworkopen.2022.52387","volume":"6","author":"H Stocker","year":"2023","unstructured":"Stocker H, Beyer L, Trares K, Perna L, Rujescu D, Holleczek B, et al. Association of kidney function with development of Alzheimer disease and other dementias and dementia-related blood biomarkers. JAMA Netw Open. 2023;6(1):e2252387.","journal-title":"JAMA Netw Open."},{"issue":"5","key":"1658_CR19","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M, Fern\u00e1ndez-Lebrero A, Garc\u00eda-Escobar G, Gonz\u00e1lez-Ortiz F, et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 2023;19(5):1913\u201324.","journal-title":"Alzheimers Dement."},{"issue":"4","key":"1658_CR20","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/alz.12801","volume":"19","author":"C Rabe","year":"2023","unstructured":"Rabe C, Bittner T, Jethwa A, Suridjan I, Manuilova E, Friesenhahn M, et al. Clinical performance and robustness evaluation of plasma amyloid-\u03b242\/40 prescreening. Alzheimers Dement J Alzheimers Assoc. 2023;19(4):1393\u2013402.","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"issue":"1","key":"1658_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","volume":"14","author":"AL Benedet","year":"2022","unstructured":"Benedet AL, Brum WS, Hansson O, Alzheimer\u2019s Disease Neuroimaging Initiative, Karikari TK, Zimmer ER, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14(1):26.","journal-title":"Alzheimers Res Ther."},{"key":"1658_CR22","doi-asserted-by":"crossref","unstructured":"Cullen NC, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Bittner T, Suridjan I, et al. Test-retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models. Alzheimers Dement J Alzheimers Assoc. 2022.","DOI":"10.1002\/alz.12706"},{"issue":"11","key":"1658_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1515\/cclm-2022-0480","volume":"60","author":"SH Christensen","year":"2022","unstructured":"Christensen SH, Hviid CVB, Madsen AT, Parkner T, Winther-Larsen A. Short-term biological variation of serum glial fibrillary acidic protein. Clin Chem Lab Med CCLM. 2022;60(11):1813\u20139.","journal-title":"Clin Chem Lab Med CCLM."},{"issue":"4","key":"1658_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1515\/cclm-2020-1276","volume":"60","author":"CVB Hviid","year":"2022","unstructured":"Hviid CVB, Madsen AT, Winther-Larsen A. Biological variation of serum neurofilament light chain. Clin Chem Lab Med. 2022;60(4):569\u201375.","journal-title":"Clin Chem Lab Med."},{"key":"1658_CR25","doi-asserted-by":"publisher","first-page":"117608","DOI":"10.1016\/j.cca.2023.117608","volume":"551","author":"A Carobene","year":"2023","unstructured":"Carobene A, Maiese K, Abou-Diwan C, Locatelli M, Serteser M, Coskun A, et al. Biological variation estimates for serum neurofilament light chain in healthy subjects. Clin Chim Acta Int J Clin Chem. 2023;551:117608.","journal-title":"Clin Chim Acta Int J Clin Chem."},{"key":"1658_CR26","doi-asserted-by":"crossref","unstructured":"Brum WS, Ashton NJ, Simr\u00e9n J, di Molfetta G, Karikari TK, Benedet AL, et al. Biological variation estimates of Alzheimer\u2019s disease plasma biomarkers in healthy individuals. Alzheimers Dement J Alzheimers Assoc. 2023.","DOI":"10.1101\/2023.08.09.23293841"},{"issue":"12","key":"1658_CR27","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2022;18(12):2669\u201386.","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"issue":"4","key":"1658_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1258\/000456307780945633","volume":"44","author":"C Ric\u00f3s","year":"2007","unstructured":"Ric\u00f3s C, Iglesias N, Garc\u00eda-Lario JV, Sim\u00f3n M, Cava F, Hern\u00e1ndez A, et al. Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem. 2007;44(4):343\u201352.","journal-title":"Ann Clin Biochem."},{"issue":"3","key":"1658_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1373\/clinchem.2017.281808","volume":"64","author":"AK Aarsand","year":"2018","unstructured":"Aarsand AK, R\u00f8raas T, Fernandez-Calle P, Ricos C, D\u00edaz-Garz\u00f3n J, Jonker N, et al. The biological variation data critical appraisal checklist: a standard for evaluating studies on biological variation. Clin Chem. 2018;64(3):501\u201314.","journal-title":"Clin Chem."},{"issue":"4","key":"1658_CR30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/2211068215589580","volume":"21","author":"DH Wilson","year":"2016","unstructured":"Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, et al. The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J Lab Autom. 2016;21(4):533\u201347.","journal-title":"J Lab Autom."},{"issue":"5","key":"1658_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol."},{"issue":"5","key":"1658_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol (Berl). 2021;141(5):709\u201324.","journal-title":"Acta Neuropathol (Berl)."},{"issue":"3","key":"1658_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res."},{"issue":"11","key":"1658_CR34","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1212\/01.wnl.0000434309.85312.19","volume":"55","author":"PS Mathuranath","year":"2000","unstructured":"Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer\u2019s disease and frontotemporal dementia. Neurology. 2000;55(11):1613\u201320. 2000\/12\/13 udg.","journal-title":"Neurology."},{"issue":"3","key":"1658_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"issue":"3","key":"1658_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement."},{"issue":"1","key":"1658_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology."},{"issue":"Pt 9","key":"1658_CR38","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456\u201377. 2011\/08\/04 udg.","journal-title":"Brain."},{"issue":"3","key":"1658_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","volume":"28","author":"P Sachdev","year":"2014","unstructured":"Sachdev P, Kalaria R, O\u2019Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206\u201318.","journal-title":"Alzheimer Dis Assoc Disord."},{"issue":"8","key":"1658_CR40","first-page":"714","volume":"21","author":"A Charidimou","year":"2022","unstructured":"Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective. MRI-neuropathology diagnostic accuracy study Lancet Neurol. 2022;21(8):714\u201325.","journal-title":"MRI-neuropathology diagnostic accuracy study. Lancet Neurol."},{"issue":"4","key":"1658_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y (Lucy), Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med."},{"key":"1658_CR42","doi-asserted-by":"crossref","unstructured":"Fraser CG. Reference change values. Clin Chem Lab Med. 2012 [henvist 22. april 2024];50(5). Tilg\u00e6ngelig hos: https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm.2011.733\/html.","DOI":"10.1515\/cclm.2011.733"},{"issue":"7","key":"1658_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/10408363.2022.2070905","volume":"59","author":"A Coskun","year":"2022","unstructured":"Coskun A, Sandberg S, Unsal I, Serteser M, Aarsand AK. Personalized reference intervals: from theory to practice. Crit Rev Clin Lab Sci. 2022;59(7):501\u201316.","journal-title":"Crit Rev Clin Lab Sci."},{"issue":"7","key":"1658_CR44","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol."},{"issue":"9","key":"1658_CR45","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801.","journal-title":"Nat Med."},{"issue":"4","key":"1658_CR46","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 2023;80(4):360\u20139.","journal-title":"JAMA Neurol."},{"issue":"4","key":"1658_CR47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"issue":"4","key":"1658_CR48","doi-asserted-by":"publisher","first-page":"e12512","DOI":"10.1002\/dad2.12512","volume":"15","author":"AH Simonsen","year":"2023","unstructured":"Simonsen AH, Gleerup HS, Musaeus CS, Sellebjerg F, Hansen MB, S\u00f8ndergaard HB, et al. Neurofilament light chain levels in serum among a large mixed memory clinic cohort: Confounders and diagnostic usefulness. Alzheimers Dement Amst Neth. 2023;15(4):e12512.","journal-title":"Alzheimers Dement Amst Neth."},{"key":"1658_CR49","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.dadm.2019.08.002","volume":"11","author":"AL Benedet","year":"2019","unstructured":"Benedet AL, Ashton NJ, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS, et al. Plasma neurofilament light associates with Alzheimer\u2019s disease metabolic decline in amyloid-positive individuals. Alzheimers Dement Amst Neth. 2019;11:679\u201389.","journal-title":"Alzheimers Dement Amst Neth."},{"issue":"17","key":"1658_CR50","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.18632\/aging.102220","volume":"11","author":"H Hu","year":"2019","unstructured":"Hu H, Chen KL, Ou YN, Cao XP, Chen SD, Cui M, et al. Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. Aging. 2019;11(17):6904\u201314.","journal-title":"Aging."},{"issue":"5","key":"1658_CR51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer\u2019s disease neuroimaging initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366.","journal-title":"JAMA Neurol."},{"issue":"7","key":"1658_CR52","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791\u20139.","journal-title":"JAMA Neurol."},{"issue":"2","key":"1658_CR53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383.","journal-title":"Nat Med."},{"issue":"6","key":"1658_CR54","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/ana.25874","volume":"88","author":"KB Rajan","year":"2020","unstructured":"Rajan KB, Aggarwal NT, McAninch EA, Weuve J, Barnes LL, Wilson RS, et al. Remote blood biomarkers of longitudinal cognitive outcomes in a population study. Ann Neurol. 2020;88(6):1065\u201376.","journal-title":"Ann Neurol"},{"key":"1658_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neurobiolaging.2020.05.011","volume":"94","author":"MA Sugarman","year":"2020","unstructured":"Sugarman MA, Zetterberg H, Blennow K, Tripodis Y, McKee AC, Stein TD, et al. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer\u2019s disease. Neurobiol Aging. 2020;94:60\u201370.","journal-title":"Neurobiol Aging."},{"issue":"2","key":"1658_CR56","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","volume":"4","author":"Y Guo","year":"2024","unstructured":"Guo Y, You J, Zhang Y, Liu WS, Huang YY, Zhang YR, et al. Plasma proteomic profiles predict future dementia in healthy adults. Nat Aging. 2024;4(2):247\u201360.","journal-title":"Nat Aging."}],"updated-by":[{"DOI":"10.1186\/s13195-025-01746-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000}}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01658-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T07:03:01Z","timestamp":1747810981000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01658-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01658-7","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13195-025-01746-2","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article was revised: the coloured lines legend (red AD, blue nonAD) to Figure 2 were inadvertently omitted.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-025-01746-2","URL":"https:\/\/doi.org\/10.1186\/s13195-025-01746-2","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Danish Research Ethics Committee (H-21044863) and followed the tenets of the 1975 Helsinki Declaration. The study was registered at clinicaltrials.gov (NCT05175664). Written informed consent was obtained from each participant prior to enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KF serves on a scientific advisory board for Novo Nordisk and Eisai, has given lectures in symposia for Novo Nordisk, and has served or serves as principal investigator in trials for Roche, Biogen, AbbVie, Novo Nordisk and Roche Diagnostics for which fees is paid to the institution and no personal remuneration is received. KF also serves as Editor-in-Chief for Alzheimer\u00b4s Research and Therapy (Springer) for which personal remuneration is paid. The other authors have no conflict of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}